Qwadra secures exclusive BEGO Medical license for conveyor-belt 3D printing of foot orthotic insoles

Qwadra, the Spanish parent company of the PodoPrinter brand, has secured an exclusive patent license from BEGO Medical covering conveyor-belt-based 3D printing technology for the continuous production of custom foot orthotic insoles. The agreement grants Qwadra exclusive commercial development rights across Europe and international markets for printers that use a continuously moving, laterally inclined belt instead of a static build platform, enabling sequential part printing and automatic ejection without machine downtime. CEO Luc Boronat stated the deal validates the company's positioning in a competitive niche and allows it to invest more transparently in innovation, service, and international expansion. The license specifically covers this belt-printing configuration for the orthotic insole segment, a market where dimensional accuracy and material consistency are clinical requirements rather than optional optimizations.

This deal fits a recurring pattern in the AM industry where a smaller specialist secures a defensible IP position in a narrow but commercially meaningful application segment. The foot orthotic market has been an active AM adoption area for over a decade, driven by high customization demand and relatively simple geometries, with most production lines relying on SLS or MJF using PA11 or PA12 powders. Qwadra's conveyor-belt FFF approach differentiates through lower equipment cost and continuous production capability, making it particularly attractive for medium-volume orthotic labs that do not require the upper material performance ceiling of powder-bed fusion. The exclusive license gives Qwadra a protected position in this specific technical configuration, allowing it to scale commercial operations without direct replication risk from competitors using the same method. This follows Qwadra's 2024 strategic partnership with Create it REAL to integrate programmable foam technology into its Sona Flex and Sona Edge printers for orthotic braces and seating, showing a dual-track strategy of comfort-focused product features and production-focused throughput.

From a practical standpoint, Qwadra now has a clear IP moat in conveyor-belt printing for orthotic insoles, but the value of that moat depends entirely on its ability to convert the license into actual sales growth and lab adoption. The company must now demonstrate that its continuous production approach can deliver consistent clinical quality at volumes that justify the switch from established SLS or MJF workflows. For buyers in the orthotic lab market, this license reduces the risk of investing in Qwadra's platform, as the technology path is now legally protected, but the economic case still hinges on total cost per insole compared to incumbent powder-bed solutions.